Pharmafile Logo
Pharmafocus logo
Advanced Search

avastin

Showing 15 posts of 94 posts found.

Avastin image

Scotland ‘no’ to Avastin

October 9, 2012
Sales and Marketing NICE, Roche, Scotland, avastin

Roche has slammed the Scottish Medicines Consortium (SMC)’s decision not to recommend Avastin for women with advanced ovarian cancer in …

News
Zaltrap image

Sanofi’s Zaltrap data published

October 8, 2012
Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin

Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …

News
Lucentis image

NICE does Lucentis U-turn

October 5, 2012
Sales and Marketing Lucentis, NICE, Novartis, Roche, avastin

NICE has done a U-turn over its previous verdict on Novartis’ Lucentis, now recommending the drug in draft guidance to …

News

FDA approves Bayer’s Stivarga

October 1, 2012
Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin

The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …

News
lilly corporate hq image

Lilly suffers late-stage cancer blow

September 10, 2012
Research and Development, Sales and Marketing Alimta, Cancer, avastin, lilly, oncology

Eli Lilly suffered a blow to its oncology programme when a new combination treatment failed to improve overall survival in …

News
Avastin image

Another NICE no for Avastin in breast cancer

August 22, 2012
Sales and Marketing NICE, avastin, breast cancer, rejection

Roche’s Avastin has been rejected once again for use in breast cancer patients.  NICE has now issued final guidance saying …

News
novartis_window

New Avastin data could be bad news for Lucentis

August 14, 2012
Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …

News
Avastin image

Avastin sees success in brain cancer trial

August 13, 2012
Research and Development, Sales and Marketing R&D, avastin, brain cancer

A late-stage study has shown that Roche’s oncology drug Avastin, when added to standard therapy, can help people with brain …

News
Pfizer image

Torisel-Avastin combo fails in kidney cancer

August 13, 2012
Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc

Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …

News
Lucentis image

Lucentis gains new licence in the US

August 13, 2012
Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD

Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …

News
Avastin image

Lucentis price cut ends PCT-Novartis dispute

July 26, 2012
Sales and Marketing ABPI, NHS, PCTs, Roche, SHIP Cluster, avastin

An NHS body has been persuaded to reverse its policy of recommending Avastin for wet AMD. The Southampton, Hampshire, Isle …

News
Microneedles image

Microneedles could transform delivery of drugs to the eye

July 24, 2012
Manufacturing and Production, Research and Development AMD, avastin, microneedles

Researchers in the US have demonstrated for the first time that drugs can be successfully delivered to the eye using …

News
Avastin pack shot

NICE no for Avastin in breast cancer

July 6, 2012
Sales and Marketing NICE, Roche, avastin, breast cancer, rejection

NICE has decided once again not to recommend Roche’s Avastin on the NHS for the first line treatment of metastatic …

News

Genentech taken to task over Avastin production

May 15, 2012
Manufacturing and Production Genentech, Phil Taylor, avastin, manufacturing

FDA inspections of a manufacturing facility for Roche/Genentech’s cancer drug Avastin (bevacizumab) uncovered a number of deficiencies which could increase …

News
Lucentis image

Novartis ponders Lucentis price cut in UK

May 8, 2012
Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access

 Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024